TRAMAZOLINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H17N3
Molecular Weight	215.2942
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

C1CN=C(NC2=C3CCCCC3=CC=C2)N1

InChI

InChIKey=QQJLHRRUATVHED-UHFFFAOYSA-N

InChI=1S/C13H17N3/c1-2-6-11-10(4-1)5-3-7-12(11)16-13-14-8-9-15-13/h3,5,7H,1-2,4,6,8-9H2,(H2,14,15,16)

HIDE SMILES / InChI

Molecular Formula	C13H17N3
Molecular Weight	215.2942
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Tramazoline is a sympathomimetic drug that is used in the form of tramazoline hydrochloride in nasal decongestant preparations. Tramazoline is an α-adrenergic receptor agonist that inhibits secretion of nasal mucus.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor alpha-2 113	Agonist 2,678		16.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Rhinitis 20	Primary		Approved 8,429	Spray-Tish

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose for adults and children six years of age and over is 1 to 2 sprays into each nostril up to four times daily as required.

Route of Administration: Nasal

In Vitro Use Guide

Binding affinity of Tramazoline against Alpha-2 adrenergic receptor measured as the ability to inhibit the specific [3H]clonidine binding (0.4 nM) to rat isolated brain membranes by 50% was 16 nM.